BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 56.87K | $3.73M | n/a | n/a |
| Q2 2026 | 134 | +3 | 120.77M | $8.70B | +10 | −6 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | n/a | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | n/a |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | n/a | −1 |
| Q2 2024 | 13 | n/a | 36.42M | $922.50M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 16.83M | +2.1% | $874.26M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | Viking Global Investors ✦ | 15.98M | -13.9% | $829.89M | 2.2% | ▼ Trim | 6 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 14.41M | +1.1% | $748.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 4 | State Street Global Advisors ✦ (passief) | 5.61M | -4.9% | $291.19M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passief) | 3.91M | +6.2% | $203.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.33M | -0.4% | $120.97M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 2.25M | +8.2% | $117.01M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Goldman Sachs Group ✦ | 2.21M | n/a | $114.74M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | Fidelity (FMR) ✦ | 1.70M | -16.1% | $88.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 1.57M | +63.1% | $81.42M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 1.05M | n/a | $54.79M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | Wellington Management ✦ | 1.02M | +1698.5% | $52.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 13 | Adage Capital Partners ✦ | 944.85K | +213.5% | $49.08M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | JPMorgan Chase ✦ | 588.23K | n/a | $30.55M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 15 | PRIMECAP Management ✦ | 576.37K | -2.1% | $29.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 322.25K | +31.0% | $16.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Millennium Management ✦ | 170.44K | -72.5% | $8.85M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 18 | Marshall Wace ✦ | 101.24K | -76.0% | $5.26M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 98.83K | -37.4% | $5.13M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Norges Bank | $84.49M | was 0.0% |
| Citadel Advisors | $14.35M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 15.30K aandelen, $1,136 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 1.28K aand · $88,980
Officer, Director · 8.72K aand · $601,868
Officer, Director · 1.80K aand · $152,436
Officer, Director · 100 aand · $8,565
Officer, Director · 8.10K aand · $679,256
Officer, Director · 1.90K aand · $154,184
Officer, Director · 17.28K aand · $1.42M
Officer, Director · 14.60K aand · $1.21M
Officer, Director · 1.20K aand · $100,444
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie
4.2% van klasse · Originele SEC-indiening bekijken ↗
5.0% van klasse · Originele SEC-indiening bekijken ↗